Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical PatientsAlexander T Cohen, Victor F. Tapson, Theodore E. Spiro et al.|New England Journal of Medicine|2013Cited by 603
A nitric oxide processing defect of red blood cells created by hypoxia: Deficiency of S-nitrosohemoglobin in pulmonary hypertensionT. McMahon, Jonathan S. Stamler, Gregory S. Ahearn et al.|Proceedings of the National Academy of Sciences|2005Cited by 132
Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocolAlexander Thomas Cohen, Victor F. Tapson, Theodore E. Spiro et al.|Journal of Thrombosis and Thrombolysis|2011Cited by 120
D‐dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trialAlexander T. Cohen, Paul Burton, Theodore E. Spiro et al.|Journal of Thrombosis and Haemostasis|2014Cited by 115
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trialKarin Hardt, Jeffrey J. Stoddard, Christoph D. Spinner et al.|The Lancet Infectious Diseases|2022Cited by 88